2. Academic Validation
  3. Identification of a novel competitive inhibitor of p38alpha MAPK by a human PBMC screen

Identification of a novel competitive inhibitor of p38alpha MAPK by a human PBMC screen

  • Biochem Biophys Res Commun. 2007 Jan 19;352(3):656-61. doi: 10.1016/j.bbrc.2006.11.069.
Yu-Chih Liu 1,  Chia-Chen Ko,  Fong-Chi Cheng,  Po-Tsang Huang,  Kuo-Long Lou,  Lu-Ping Chow
Affiliations

Affiliation

  • 1 Graduate Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
PMID: 17141198 DOI: 10.1016/j.bbrc.2006.11.069
Abstract

The pro-inflammatory cytokines TNF-alpha and IL-1beta are two of the important mediators involved in the several chronic inflammatory diseases. We used the release of TNF-alpha and IL-1beta from lipopolysaccharide-stimulated human PBMC as inflammatory indexes to discover the potential anti-inflammatory candidates. Among near 500 chemical compounds, MT4 had the suppressive action on the release of TNF-alpha and IL-1beta in PBMC with IC50 values of 22 and 44 nM, respectively. After verified the MT4 inhibitory mechanism, the results revealed that p38alpha and p38beta MAPK activity was inhibited by MT4 with an IC50 value of 0.13 and 0.55 microM, respectively. Further characterization of Enzyme kinetics showed the binding mode of MT4 was competitive with the ATP substrate-binding site of p38alpha MAPK.

Figures
Products